{"title":"印度艾哈迈达巴德年轻成年女性（18-30岁）乳腺癌的临床病理特征和预后：一项单中心、回顾性观察性研究","authors":"Ajinkya Pawar, Poojitha Yalla, Mohit Sharma, Ketul Puj, Jebin Aaron, Vikas Warikoo, Abhijeet Salunke, Shashank Pandya","doi":"10.1016/j.lansea.2025.100643","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer in young adult women is a rapidly growing group of cancer patients in India which needs to be addressed with urgency. Despite increasing global focus on breast cancer in young women, data from India remain scarce. Considering this gap, we undertook this study to analyse the clinicopathological characteristics and prognostic outcomes of young adult women (aged 18–30 years) with breast cancer in Ahmedabad, India.</div></div><div><h3>Methods</h3><div>This was a retrospective observational study of a prospectively maintained database of 201 patients with breast cancer (aged 18–30 years) treated in a high-volume tertiary centre in Ahmedabad, India, from January 2015 to December 2020. Patients were followed up until June 2023. The demographic parameters, clinicopathological characteristics and survival of all patients were studied. Statistical analyses were done using SPSS and DATAtab.</div></div><div><h3>Findings</h3><div>In this study 49.2% of cases were early breast cancers, 26.8% locally advanced, and 23.8% were metastatic. The proportion of aggressive cancers was higher with 38.8% hormone negative, 39.3% HER2-positive, 26.8% triple-negative and 50.8% grade 3. The median overall survival for all patients was 56 months (95% CI 28–84 months) and the 5-year overall survival was 48% (95% CI 40–56%). The multivariate analysis suggested that clinical stage, grade and luminal A status, significantly affected overall survival. The 5-year overall survival and disease-free survival of patients undergoing surgery were 65% (95% CI 57–74%) and 56% (95% CI 47–65%) respectively.</div></div><div><h3>Interpretation</h3><div>The 5-year overall survival rate of 48% among young adult women with breast cancer included in this study is poor compared to the 77% observed in high-income countries in the western parts of the world. Adoption of appropriate and aggressive treatment strategies may enhance the outcomes in this age group of women with breast cancer.</div></div><div><h3>Funding</h3><div>None.</div></div>","PeriodicalId":75136,"journal":{"name":"The Lancet regional health. Southeast Asia","volume":"40 ","pages":"Article 100643"},"PeriodicalIF":6.2000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinicopathological characteristics and prognostic outcomes of young adult women (aged 18–30 years) with breast cancer in Ahmedabad, India: a single-centre, retrospective observational study\",\"authors\":\"Ajinkya Pawar, Poojitha Yalla, Mohit Sharma, Ketul Puj, Jebin Aaron, Vikas Warikoo, Abhijeet Salunke, Shashank Pandya\",\"doi\":\"10.1016/j.lansea.2025.100643\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Breast cancer in young adult women is a rapidly growing group of cancer patients in India which needs to be addressed with urgency. Despite increasing global focus on breast cancer in young women, data from India remain scarce. Considering this gap, we undertook this study to analyse the clinicopathological characteristics and prognostic outcomes of young adult women (aged 18–30 years) with breast cancer in Ahmedabad, India.</div></div><div><h3>Methods</h3><div>This was a retrospective observational study of a prospectively maintained database of 201 patients with breast cancer (aged 18–30 years) treated in a high-volume tertiary centre in Ahmedabad, India, from January 2015 to December 2020. Patients were followed up until June 2023. The demographic parameters, clinicopathological characteristics and survival of all patients were studied. Statistical analyses were done using SPSS and DATAtab.</div></div><div><h3>Findings</h3><div>In this study 49.2% of cases were early breast cancers, 26.8% locally advanced, and 23.8% were metastatic. The proportion of aggressive cancers was higher with 38.8% hormone negative, 39.3% HER2-positive, 26.8% triple-negative and 50.8% grade 3. The median overall survival for all patients was 56 months (95% CI 28–84 months) and the 5-year overall survival was 48% (95% CI 40–56%). The multivariate analysis suggested that clinical stage, grade and luminal A status, significantly affected overall survival. The 5-year overall survival and disease-free survival of patients undergoing surgery were 65% (95% CI 57–74%) and 56% (95% CI 47–65%) respectively.</div></div><div><h3>Interpretation</h3><div>The 5-year overall survival rate of 48% among young adult women with breast cancer included in this study is poor compared to the 77% observed in high-income countries in the western parts of the world. Adoption of appropriate and aggressive treatment strategies may enhance the outcomes in this age group of women with breast cancer.</div></div><div><h3>Funding</h3><div>None.</div></div>\",\"PeriodicalId\":75136,\"journal\":{\"name\":\"The Lancet regional health. Southeast Asia\",\"volume\":\"40 \",\"pages\":\"Article 100643\"},\"PeriodicalIF\":6.2000,\"publicationDate\":\"2025-07-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet regional health. Southeast Asia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772368225001143\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet regional health. Southeast Asia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772368225001143","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
摘要
在印度，年轻成年女性乳腺癌是一个快速增长的癌症患者群体，需要紧急处理。尽管全球越来越关注年轻女性的乳腺癌，但来自印度的数据仍然很少。考虑到这一差距，我们进行了这项研究，分析了印度艾哈迈达巴德年轻成年女性（18-30岁）乳腺癌的临床病理特征和预后结果。方法：本研究是一项回顾性观察性研究，对2015年1月至2020年12月在印度艾哈迈达巴德一个大容量三级中心接受治疗的201例乳腺癌患者（18-30岁）进行前瞻性数据库维护。患者随访至2023年6月。研究了所有患者的人口学参数、临床病理特征和生存率。采用SPSS和DATAtab进行统计分析。发现49.2%的病例为早期乳腺癌，26.8%为局部晚期，23.8%为转移性乳腺癌。侵袭性肿瘤占比较高，激素阴性38.8%，her2阳性39.3%，三阴性26.8%，3级50.8%。所有患者的中位总生存期为56个月（95% CI 28-84个月），5年总生存期为48% （95% CI 40-56%）。多因素分析表明，临床分期、分级和腔内A状态对总生存率有显著影响。手术患者的5年总生存率和无病生存率分别为65% （95% CI 57-74%）和56% （95% CI 47-65%）。本研究中年轻成年女性乳腺癌患者的5年总生存率为48%，与世界西部高收入国家的77%相比很低。采用适当和积极的治疗策略可以提高这一年龄组乳腺癌妇女的预后。
Clinicopathological characteristics and prognostic outcomes of young adult women (aged 18–30 years) with breast cancer in Ahmedabad, India: a single-centre, retrospective observational study
Background
Breast cancer in young adult women is a rapidly growing group of cancer patients in India which needs to be addressed with urgency. Despite increasing global focus on breast cancer in young women, data from India remain scarce. Considering this gap, we undertook this study to analyse the clinicopathological characteristics and prognostic outcomes of young adult women (aged 18–30 years) with breast cancer in Ahmedabad, India.
Methods
This was a retrospective observational study of a prospectively maintained database of 201 patients with breast cancer (aged 18–30 years) treated in a high-volume tertiary centre in Ahmedabad, India, from January 2015 to December 2020. Patients were followed up until June 2023. The demographic parameters, clinicopathological characteristics and survival of all patients were studied. Statistical analyses were done using SPSS and DATAtab.
Findings
In this study 49.2% of cases were early breast cancers, 26.8% locally advanced, and 23.8% were metastatic. The proportion of aggressive cancers was higher with 38.8% hormone negative, 39.3% HER2-positive, 26.8% triple-negative and 50.8% grade 3. The median overall survival for all patients was 56 months (95% CI 28–84 months) and the 5-year overall survival was 48% (95% CI 40–56%). The multivariate analysis suggested that clinical stage, grade and luminal A status, significantly affected overall survival. The 5-year overall survival and disease-free survival of patients undergoing surgery were 65% (95% CI 57–74%) and 56% (95% CI 47–65%) respectively.
Interpretation
The 5-year overall survival rate of 48% among young adult women with breast cancer included in this study is poor compared to the 77% observed in high-income countries in the western parts of the world. Adoption of appropriate and aggressive treatment strategies may enhance the outcomes in this age group of women with breast cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
